Holen Sie sich die Stockscreener-App
196.19
1.54%
2.98
Handel nachbörslich:
194.41
-1.78
-0.91%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$193.21
Offen:
$192.83
24-Stunden-Volumen:
5.95M
Relative Volume:
1.31
Marktkapitalisierung:
$138.86B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
37.92
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
+10.74%
1M Leistung:
+13.53%
6M Leistung:
-14.82%
1J Leistung:
-2.62%
1-Tages-Spanne:
$192.29
$196.19
1-Wochen-Bereich:
$175.00
$197.57
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Danaher clears new AI milestone with Masimo, shares react on NYSE - Ad-hoc-news.de
Danaher Corp Shs Unsponsored Brazilian Depository Receipt Repr 0.035714285 Sh - TradingView
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer - The Motley Fool
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why Danaher (DHR) Stock Rose Today - Quiver Quantitative
Danaher clears FDA hurdle with Masimo, shares extend rebound on NYSE - Ad-hoc-news.de
Why Is (NYSE:DHR) Back in Focus Following AI Monitoring Approval? - Kalkine Media
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors - Zacks Investment Research
Danaher $172.5 Million Securities Class Action Settlement - Claim Depot
Is Danaher (DHR) Using Masimo’s New FDA-Cleared AI Tool To Redefine Its Medtech Edge? - Yahoo Finance
A Look at Danaher Corp (DHR) After 5.5% Gain -- GF Value $236.97 vs Price $188.87 - GuruFocus
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher Corp Stock (DHR) Moved Up by 4.91% on Jun 24: What Investors Need To Know - TradingKey
Danaher boosts product portfolio with the acquisition of Masimo - MSN
HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why - Insider Monkey
How FDA Clearance of AI Opioid-Respiratory Monitoring Could Shape Danaher’s (DHR) Clinical Data Advantage - simplywall.st
Danaher achieves FDA clearance for Masimo feature, shares steady on NYSE - Ad-hoc-news.de
Danaher Corp (DHR) Institutional Confidence - TradingKey
Deals tracker: Hackensack Meridian Health explores merger - Modern Healthcare News
Danaher plans July 21 earnings call, slide deck at 6 a.m. ET - Stock Titan
Danaher Finalizes $9.9B Purchase of Masimo - Orange County Business Journal
Danaher (DHR) Achieves FDA Clearance for Wearable Monitoring Tec - GuruFocus
Danaher Corp (DHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Danaher Stockweekly outlook with earnings and events ahead - Ad-hoc-news.de
Medtech business update: Spectrum Vascular acquires Piccolo Medical, Danaher acquires Masimo - Today's Medical Developments
From bench chaos to calm order, Cytiva ÄKTA pure quietly cleans up protein prep - AD HOC NEWS
Lodi's largest private employer expands with fifth building - The Business Journals
Danaher Corp (DHR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Danaher Corp (DHR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Danaher Corp (DHR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Danaher Corp (DHR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Danaher Corp (DHR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Danaher Corp (DHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDBS and Alchemi partner to accelerate biopharma regulatory filings with compliant AI agents - PR Newswire
Danaher’s Cepheid Ebola Tests Highlight Diagnostics Role In Global Crises - Yahoo! Finance Canada
Masimo CEO stepping down following acquisition by Danaher - Modern Healthcare
Danaher Corporation’s (DHR) Recovery Fell Short of Investor Expectations - Yahoo Finance
Piper Sandler Begins Coverage of Danaher (DHR) While Waiting for New Growth Catalysts - Insider Monkey
Danaher Corp. Stock (US2358511028): Diagnostics expansion keeps diversified healthcare group in focu - AD HOC NEWS
Danaher Deepens Diagnostics Reach As Masimo Deal Reshapes Healthcare Focus - Yahoo Finance
Danaher completes acquisition of Masimo, company delists from Nasdaq By Investing.com - Investing.com Nigeria
Danaher Corp. Stock (US2358511028): shares in focus after quiet trading week - AD HOC NEWS
Is Danaher stock underperforming the S&P 500? - MSN
Danaher Masimo Deal Strengthens S&P 500 Healthcare Growth Story - Kalkine Media
Masimo (MASI) director equity cashed out at $180 per share in Danaher merger - Stock Titan
Masimo (MASI) EVP equity cashed out and converted in Danaher merger - Stock Titan
Masimo (MASI) CCO reports merger-driven cancellation and conversion of equity awards - Stock Titan
Masimo (MASI) CHRO equity canceled, cashed out and rolled into Danaher - Stock Titan
Masimo (MASI) GC reports RSU disposals as Danaher merger converts awards - Stock Titan
Masimo (MASI) CMO disposes RSUs, options as Danaher merger closes - Stock Titan
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):